Prospective, single centre, proof-of-concept trial of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV patients
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 19 Dec 2022 New trial record
- 26 Oct 2022 Results (n=100) presented at the 16th International Congress on Drug Therapy and HIV Infection